Pladsen AV, Smebye ML, Garred Ø, Borgen E, Egeland EV, Haugen MH, Dahle MA, Prasmickaite L, Mælandsmo GM, Hovig E, Nakken S, Østgaard A, Bergheim IR, Reinertsen K, Ohnstad HO, Schlichting E, Skjerven HK, Dale AB, Wist E, Naume B, Russnes HG, Lingjærde OC, Engebraaten O(2026) DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast Cancer Clin Cancer Res(in press) DOI 10.1158/1078-0432.CCR-26-2212, PubMed 42870529
Emaldi M, Sendino M, Muñoz J, Nunes-Xavier CE(2026) AXL and enolase 2 associate with therapy resistance to tyrosine kinase inhibitors lenvatinib and cabozantinib in renal cancer cells J Proteomics, 333, 105743(in press) DOI 10.1016/j.jprot.2026.105743, PubMed 42869109
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM(2026) Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy Mol Ther(in press) DOI 10.1016/j.ymthe.2026.09.027, PubMed 42800469